Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | PRNP | P04156 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4316782 | 0.79 | MEN1 (0.36) | MEN1KMT2ACSNK2A2CSNK2A1RAB9A | |
| SCHEMBL355361 | 0.79 | PDPK1 (0.37) | MEN1KMT2ACSNK2A2CSNK2A1RAB9A | |
| SCHEMBL16146852 | 0.79 | MEN1 (0.36) | MEN1KMT2ACSNK2A2CSNK2A1RAB9A | |
| SCHEMBL9884053 | 0.79 | MEN1 (0.36) | MEN1KMT2ACSNK2A2CSNK2A1RAB9A | |
| SCHEMBL2997391 | 0.79 | CSNK2A1 (0.36) | MEN1KMT2ACSNK2A2CSNK2A1RAB9A | |
| SCHEMBL5145883 | 0.79 | CSNK2A1 (0.36) | MEN1KMT2ACSNK2A2CSNK2A1RAB9A | |
| SCHEMBL497198 | 0.79 | KMT2A (0.36) | MEN1KMT2ACSNK2A2CSNK2A1RAB9A | |
| SCHEMBL16147419 | 0.76 | XDH (0.38) | MEN1KMT2ACSNK2A2CSNK2A1RAB9A | |
| SCHEMBL16146290 | 0.75 | MEN1 (0.33) | MEN1KMT2ACSNK2A2CSNK2A1RAB9A | |
| SCHEMBL22700363 | 0.75 | MEN1 (0.37) | MEN1KMT2ACSNK2A2CSNK2A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415776-B1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | NOVARTIS AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| US-9290533-B2 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B | NOVARTIS AG (CH) | 2016-03-22 | — | — | US | disclosed |
| EP-1572095-B1 | BETA-L-2'-DEOXYNUCLEOSIDES FOR USE IN THE TREATMENT OF RESISTANT HBV STRAINS | NOVARTIS AG (CH) | 2015-06-10 | — | — | EP | disclosed |
| EP-1431304-B1 | Beta - L-2'-Deoxy-Nucleosides for the treatment of Hepatitis B | NOVARTIS AG (CH) | 2014-12-03 | — | — | EP | disclosed |
| US-20130324491-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-20120264707-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8158606-B2 | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | NOVARTIS, AG (CH) | 2012-04-17 | — | — | US | disclosed |
| EP-2415776-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX Pharmaceuticals, Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110257120-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110195922-A9 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | US | disclosed |
| EP-0595826-A1 | 2'-FLUORO-2-SUBSTITUTED ADENINYL ARABINOSIDES AS ANTI-CANCER AGENTS | Southern Research Institute (US) | 1994-05-11 | — | — | EP | disclosed |
| EP-0355135-B1 | ADENOSINE DEAMINASE-STABLE ANTI-RETROVIRAL NUCLEOSIDES | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1993-08-04 | — | — | EP | disclosed |
| WO-1992020347-A1 | 2'-FLUORO-2-SUBSTITUTED ADENINYL ARABINOSIDES AS ANTI-CANCER AGENTS | SOUTHERN RESEARCH INSTITUTE (US) | 1992-11-26 | — | — | WO | disclosed |
| EP-0473708-A4 | 2-HALO-9-(2-DEOXY-2-FLUORO-B-D-ARABINOFURANOSYL) ADENINE NUCLEOSIDE DERIVATIVES | — | 1992-04-22 | — | — | EP | disclosed |
| US-5034518-A | Anticarcinogenic agents | SOUTHERN RESEARCH INSTITUTE (US) | 1991-07-23 | — | — | US | disclosed |
| US-4997926-A | Viricides | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1991-03-05 | — | — | US | disclosed |
| WO-1990014352-A1 | 2-HALO-9-(2-DEOXY-2-FLUORO-B-D-ARABINOFURANOSYL) ADENINE NUCLEOSIDE DERIVATIVES | SOUTHERN RESEARCH INSTITUTE (US) | 1990-11-29 | — | — | WO | disclosed |
| EP-0355135-A4 | ADENOSINE DEAMINASE-STABLE ANTI-RETROVIRAL NUCLEOSIDES. | SCRIPPS CLINIC RES (US) | 1990-04-09 | — | — | EP | disclosed |
| EP-0355135-A1 | ADENOSINE DEAMINASE-STABLE ANTI-RETROVIRAL NUCLEOSIDES | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1990-02-28 | — | — | EP | disclosed |
| WO-1989004662-A1 | ADENOSINE DEAMINASE-STABLE ANTI-RETROVIRAL NUCLEOSIDES | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1989-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257120-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | PNP, DUT, ATIC | MEN1 4849/4885KMT2A 2992/4885CSNK2A2 1826/4885 |
| US-20130324491-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | PNP, DUT, ATIC | MEN1 4849/4885KMT2A 2992/4885CSNK2A2 1826/4885 |
| US-20110195922-A9 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | PNP, DUT, ATIC | MEN1 4849/4885KMT2A 2992/4885CSNK2A2 1826/4885 |
| US-20120264707-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | PNP, DUT, ATIC | MEN1 4849/4885KMT2A 2992/4885CSNK2A2 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.